Clinical trials
Phase 2 Glomerulosclerosis, Focal Segmental trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2008 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 5 |
| Terminated | 5 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 |
| Amgen | 2 |
| Travere Therapeutics, Inc. | 2 |
| Akebia Therapeutics | 1 |
| Aldeyra Therapeutics, Inc. | 1 |
| Aurinia Pharmaceuticals Inc. | 1 |
| Biogen | 1 |
| Bristol-Myers Squibb | 1 |
| Dimerix Bioscience Pty Ltd | 1 |
| Duke University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glomerulosclerosis, Focal Segmental | 29 |
| Nephrosis, Lipoid | 10 |
| Proteinuria | 9 |
| Nephrotic Syndrome | 8 |
| Glomerulonephritis, IGA | 4 |
| Kidney Diseases | 4 |
| Renal Insufficiency, Chronic | 4 |
| Fibrosis | 3 |
| Nephritis, Hereditary | 3 |
| Diabetic Nephropathies | 2 |
Trials
Showing 26 to 29 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.